Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Press ReleasesNews

OXLUMO® Now Reimbursed in Canada for PH1 Treatment

  • The Pharma Data
  • July 3, 2025

OXLUMO® (Lumasiran) Secures National Reimbursement in Canada for Treatment of Primary Hyperoxaluria Type 1 Alnylam Canada ULC has announced that OXLUMO® (lumasiran), a first-in-class RNA interference (RNAi) therapeutic, is now…

Read MoreOXLUMO® Now Reimbursed in Canada for PH1 Treatment
  • Regulatory

FDA Grants Accelerated Approval to Lynozyfic for Relapsed Multiple Myeloma

  • The Pharma Data
  • July 3, 2025

Regeneron’s Lynozyfic™ Secures FDA Accelerated Approval for Heavily Pretreated Multiple Myeloma Patients Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval…

Read MoreFDA Grants Accelerated Approval to Lynozyfic for Relapsed Multiple Myeloma
  • News

Givastomig Shows Promise in 1L Gastric Cancer: I-Mab at ESMO GI 2025

  • The Pharma Data
  • July 3, 2025

I-Mab Presents Positive Phase 1b Data for Givastomig in Combination with Nivolumab and Chemotherapy in 1L Gastric Cancer at ESMO GI 2025 I-Mab (NASDAQ: IMAB), a U.S.-based global biotechnology company…

Read MoreGivastomig Shows Promise in 1L Gastric Cancer: I-Mab at ESMO GI 2025
  • ResearchPress Releases

Asahi Kasei Pharma Launches Global Phase III Trial of ART-123 for CIPN Prevention

  • The Pharma Data
  • July 3, 2025

Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical…

Read MoreAsahi Kasei Pharma Launches Global Phase III Trial of ART-123 for CIPN Prevention
  • Press Releases

WHO Launches Drive to Boost Health Taxes, Save Lives

  • The Pharma Data
  • July 3, 2025

WHO Unveils “3 by 35” Health Tax Initiative to Combat NCDs and Boost Public Revenue The World Health Organization (WHO) has launched a bold and far-reaching global campaign aimed at…

Read MoreWHO Launches Drive to Boost Health Taxes, Save Lives
  • Press Releases

Incyte Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)

  • The Pharma Data
  • July 3, 2025

Incyte Grants Equity Awards to Incoming CEO Bill Meury Under Nasdaq Rule 5635(c)(4) Incyte Corporation (Nasdaq: INCY) announced the grant of equity inducement awards to Bill Meury, marking a key…

Read MoreIncyte Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
  • Regulatory

FDA Grants Accelerated Approval to Lynozyfic™ for Relapsed or Refractory Multiple Myeloma

  • The Pharma Data
  • July 3, 2025

FDA Grants Accelerated Approval to Regeneron’s Lynozyfic™ (linvoseltamab-gcpt) for Relapsed or Refractory Multiple Myeloma Regeneron Pharmaceuticals has secured a critical milestone in oncology drug development with the U.S. Food and…

Read MoreFDA Grants Accelerated Approval to Lynozyfic™ for Relapsed or Refractory Multiple Myeloma
  • Regulatory

FDA Grants Priority Review for WINREVAIR Label Update Based on ZENITH Trial

  • The Pharma Data
  • July 3, 2025

FDA Grants Priority Review to Merck’s WINREVAIR™ Based on Landmark ZENITH Trial Showing Dramatic Reduction in Morbidity and Mortality in PAH Patients Merck (NYSE: MRK), operating as MSD outside the…

Read MoreFDA Grants Priority Review for WINREVAIR Label Update Based on ZENITH Trial
  • Business

Gilead Advances in HIV Market With Twice-Yearly Yeztugo, Leaving GSK Behind

  • The Pharma Data
  • July 2, 2025

Gilead Targets HIV Prevention Dominance With Twice-Yearly Yeztugo as GSK Mounts a Defense Gilead Sciences is taking a bold step to further entrench itself as the dominant force in HIV…

Read MoreGilead Advances in HIV Market With Twice-Yearly Yeztugo, Leaving GSK Behind
Lupin
  • Press Releases

Lupin Unveils New Consumer Healthcare Arm: LupinLife

  • The Pharma Data
  • July 2, 2025

Lupin Launches LupinLife as Independent Subsidiary to Strengthen Focus on India’s Self-Care Market Global pharmaceutical leader Lupin Limited has announced a significant strategic move to bolster its consumer healthcare operations.…

Read MoreLupin Unveils New Consumer Healthcare Arm: LupinLife
  • Research

WHO-backed testing model boosts mpox, HIV, and syphilis response

  • The Pharma Data
  • July 2, 2025

As mpox cases surge once again in parts of Central Africa, the Democratic Republic of the Congo (DRC) is leading a bold, innovative strategy by integrating HIV and syphilis testing…

Read MoreWHO-backed testing model boosts mpox, HIV, and syphilis response
  • News

Suriname Officially Certified Malaria-Free by WHO

  • The Pharma Data
  • July 2, 2025

Suriname Becomes First Amazon Nation to Earn WHO Malaria-Free Certification In a historic public health milestone, the Republic of Suriname has been officially certified as malaria-free by the World Health…

Read MoreSuriname Officially Certified Malaria-Free by WHO
PrevNext
UK Biotech Day
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Synthetic Design Lab Debuts First Logic-Gated ADC at AACR 2026, Delivering ≥10X Enhanced Targeted Cancer Cell Killing
  • Lundbeck Showcases Real-World Improvements in Migraine-Related Cognitive Symptoms with VYEPTI® at AAN 2026
  • Zai Lab Highlights Preclinical Data Showing ZL-1503 Delivers Rapid Itch Relief and Anti-Inflammatory Effects in Atopic Diseases
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.